vTv Therapeutics director granted 6,000 stock options
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
SPIEGELMAN DANIEL K reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. director Daniel K. Spiegelman received a grant of stock options, giving him the right to buy 6,000 shares of Class A Common Stock at $35.08 per share. These options expire on June 26, 2036 and are part of his director compensation.
The options vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, conditioned on his continued board service through vesting. Following this grant, Spiegelman holds options on a total of 16,000 shares.
Insider Trade Summary
Grant/Award: 6,000 shares
Grant/Award
1 txn
Insider
SPIEGELMAN DANIEL K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director stock option (right to buy) | 6,000 | $35.08 | $210K |
Holdings After Transaction:
Director stock option (right to buy) — 16,000 contracts (Direct)
Footnotes (1)
- F1. The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
Key Figures
Options granted: 6,000 options
Exercise price: $35.08 per share
Total options after grant: 16,000 options
+3 more
6 metrics
Options granted
6,000 options
Director stock option grant on June 26, 2026
Exercise price
$35.08 per share
Conversion or exercise price of granted options
Total options after grant
16,000 options
Derivative securities beneficially owned following transaction
Expiration date
June 26, 2036
Option expiration date
Underlying shares
6,000 shares
Underlying Class A Common Stock for this option grant
Vesting trigger date
June 26, 2027
Earlier of June 26, 2027 or 2027 annual meeting, subject to service
Key Terms
Director stock option (right to buy), Class A Common Stock, annual general meeting of shareholders, vesting
4 terms
Director stock option (right to buy) financial
"Security title is listed as "Director stock option (right to buy)" in the transaction."
Class A Common Stock financial
"The underlying security title for the option is "Class A Common Stock"."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
vesting financial
"The option vests on the earlier of June 26, 2027 and the 2027 annual meeting."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did vTv Therapeutics (VTVT) disclose about director Daniel Spiegelman?
vTv Therapeutics disclosed that director Daniel K. Spiegelman received a grant of stock options for 6,000 shares. These options are part of his director compensation and give him the right to buy Class A Common Stock at a fixed exercise price.
How many stock options did the vTv Therapeutics director receive in this Form 4?
Daniel K. Spiegelman received options covering 6,000 shares of Class A Common Stock. The Form 4 shows this as a derivative grant, increasing his total option holdings to 16,000 shares following the transaction reported on June 26, 2026.
What is the exercise price of Daniel Spiegelman’s vTv Therapeutics options?
The exercise price of the newly granted options is $35.08 per share. This means Spiegelman can buy vTv Therapeutics Class A Common Stock at that fixed price once the options vest, regardless of the market price at that future time.
When do Daniel Spiegelman’s new vTv Therapeutics options vest?
The options vest on the earlier of June 26, 2027 or the date of vTv Therapeutics’ 2027 annual general meeting. Vesting is subject to his continued service on the board of directors through the applicable vesting date, as described in the footnote.
When do the vTv Therapeutics director stock options expire?
The newly granted stock options expire on June 26, 2036. After this expiration date, Daniel K. Spiegelman can no longer exercise the options to purchase shares, even if they have vested and were otherwise exercisable before that date.
How many vTv Therapeutics options does Daniel Spiegelman hold after this grant?
After this grant, Daniel K. Spiegelman holds options on 16,000 shares in total. The Form 4 explicitly lists 16,000 as the total derivative securities beneficially owned following the reported transaction, reflecting the cumulative position after the 6,000-share grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
